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Abstract 
The current COVID-19 pandemic, caused by the SARS-CoV-2 virus (Severe Acute 
Respiratory Syndrome-Coronavirus-2), represents the largest medical challenge in 
decades. It has exposed unexpected cardiovascular vulnerabilities at all stages of 
the disease (pre-infection, acute phase and subsequent chronic phase). The major 
cardiometabolic drivers identified to have epidemiological and mechanistic 
associations with COVID-19 are abnormal adiposity, dysglycemia, dyslipidemia, and 
hypertension. Hypertension is of particular interest, because components of the 
renin-angiotensin system (RAS), which are critically involved in the pathophysiology 
of hypertension, are also implicated in COVID-19.  Specifically ACE2, a 
multifunctional protein of the RAS, which is part of the protective axis of the RAS, is 
also the receptor through which SARS-CoV-2 enters host cells causing viral 
infection. Cardiovascular and cardiometabolic co-morbidities not only predispose to 
COVID-19, but are complications of SARS-CoV-2 infection. In addition, increasing 
evidence indicates that acute kidney injury is common in COVID-19, that it occurs 
early and in temporal association with respiratory failure and is associated with poor 
prognosis, especially in the presence of cardiovascular risk factors. Here we discuss 
cardiovascular and kidney disease in the context of COVID-19 and provide recent 
advances on putative pathophysiological mechanisms linking cardiovascular disease 
and COVID-19, focusing on the RAS and ACE2 as well as the immune system and 
inflammation. We provide up-to-date information on the relationship between 
hypertension, diabetes, and COVID-19 and emphasize the major cardiovascular 
diseases associated with COVID-19. We also briefly discuss emerging 
cardiovascular complications associated with long COVID-19, notably postural 
tachycardia syndrome (POTS). 
         
 
Brief Summary.  
COVID-19 has exposed unexpected cardiovascular vulnerabilities at all stages of the 
disease, with major cardiometabolic risk factors being adiposity, dysglycemia, 
dyslipidemia, renal dysfunction and hypertension. Cardiovascular and 
cardiometabolic co-morbidities not only predispose to COVID-19, but are 
complications of the disease. This review appraises current findings in the field, and 
highlights emerging complications associated with long COVID-19 including postural 
tachycardia syndrome. 
Introduction 
The global ramifications of CoronaVIrus Disease-19 (COVID-19), caused by SARS-
CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2)), have been far-
reaching, impacting the health of millions, straining national healthcare systems 
worldwide and weakening global economic stability (1,2). Although presenting 
clinically as a respiratory infection COVID-19 is increasingly being regarded as a 
systemic disease not solely restricted to the respiratory system. Patients hospitalized 
for COVID-19 were also found to have increased rates of septic shock, acute kidney 
injury, rhabdomyolysis and disseminated intravascular coagulation (DIC) (3). 
Moreover, in addition to the lungs, COVID-19 has been found to cause dysfunction 
of multiple organs affecting the heart, kidneys and liver (4,5), and it has also been 
postulated that SARS-CoV-2 may invade the central nervous system similar to other 
coronaviruses, although conclusive data are lacking (6). Emerging evidence clearly 
indicates complex interactions between COVID-19 and the cardiovascular system, 
with poorer outcomes for those with underlying comorbidities, and the possibility of 
direct and long-lasting cardiovascular damage (7,8).  
         
Since the identification of SARS-CoV-2 in humans, a multitude of cardiovascular 
complications including myocardial injury, heart failure, arryhthmias, thromboembolic 
disease, as well as kidney disease, have been reported, with approximately 1 in 4 
patients affected (9,10) (figure 1).  Physiological stress due to hypoxia, hypotension 
and tachycardia; provocation of acute coronary syndromes or arrhythmia; direct viral 
infiltration; or the effects of systemic inflammation and coagulopathies are implicated. 
Additionally, pre-existing coronary artery disease and cardiovascular risk factors 
such as diabetes, obesity, chronic kidney disease or hypertension are associated 
with increased risk of severe COVID-19 infection and mortality (11,12). These 
associations have been linked to the important role of angiotensin converting 
enzyme 2 (ACE2), a component of the renin angiotensin system (RAS), and the 
receptor through which SARS-CoV-2 mediates infection (13-16). The connection 
between SARS-CoV2 infection and cardiovascular disease is not new as other 
viruses in the Coronaviridae family including SARS-CoV and Middle East respiratory 
syndrome (MERS-CoV), have long been known to be associated with myocarditis 
and heart disease, possibly through  ACE2 tropism (17-21).  
This review provides an overview of cardiovascular,  cardiometabolic and kidney 
diseases as risks associated with COVID-19 and as complications and long-term 
sequelae of SARS-CoV-2 infection. We also highlight the importance of ACE2, a 
component of the RAS, and inflammation as key factors in COVID-19-related 
cardiovascular disease.  
Angiotensin converting enzyme 2 (ACE2) as the SARS-CoV-2 receptor and 
cardiovascular implications 
ACE2 is a carboxypeptidase that exists in both membrane-bound and soluble forms. 
The majority of the protein that comprises the N-terminal domain, including the 
         
catalytic site, of membrane-bound ACE2 is oriented extracellularly, with a 
transmembrane domain anchoring it to the cell membrane. The soluble form of 
ACE2 is cleaved and shed as the N-terminal ectodomain and is typically found in the 
circulation at low concentrations, although it may increase under pathological 
conditions (22-24). The primary physiological role of ACE2 in the RAS is its catalytic 
function to produce angiotensin-(1-9) (Ang-(1-9)) and angiotensin-(1-7) (Ang-(1-7)) 
from Ang I and Ang II respectively (25). The major product of ACE2 activity is Ang-
(1-7), which binds to the Mas receptor (MasR), inducing vasodilation and anti-
proliferative, anti-inflammatory, anti-fibrotic, anti-thrombotic, and anti-arrhythmogenic 
effects that are cardiovascular protective (26-28).  The sequence of events 
culminating in MasR activation is referred to as the ACE2-Ang-(1-7)-MasR axis and 
represents the protective side of the RAS (28-30). 
COVID-19 is attributed to SARS-CoV2, which uses ACE2 as its host cell entry 
receptor (31-33) (figure 2). ACE2 is widely expressed and is found in the heart, 
kidneys, testes, type 2 alveolar epithelial cells of the lung, enterocytes of the small 
intestine and endothelial and vascular smooth muscle cells of arteries, veins and 
lymphatics (34,35). The tissue distribution of host entry receptors is believed to 
broadly coincide with viral tropisms, and theoretically SARS-CoV-2 may be able to 
enter and infect any cell or tissue which expresses ACE2 (36,37). However, this 
notion has been challenged since ACE2-expressing human intestinal cell lines failed 
to be infected by SARS-CoV (38). Similar findings have been reported for SARS-
CoV-2 where there is a lack of evidence of ACE2 expression and replicative infection 
in human endothelial cells (39). Expression of ACE2 alone may not be sufficient for 
viral infection and other factors, such as TMPRSS2, cathepsin and other proteases 
and binding proteins may be essential (40,41).    
         
While the primary target of SARS-CoV-2 is the respiratory epithelium, there is some 
evidence that the virus via ACE2, directly invades cardiomyocytes of the heart 
causing viral myocarditis (42,43). Supporting evidence in experimental models 
showed that  pulmonary infection with SARS-CoV resulted in an ACE2-dependent 
myocardial infection with subsequent decreased ACE2 expression (44). 
Beyond its role as the SARS-CoV-2 entry receptor, ACE2 may might play an indirect 
role in the pathophysiology of COVID-19 by influencing the inflammatory response. It 
may be possible that SARS-CoV-2 binding to ACE2 causes ‘downregulation’ of 
ACE2 and with reduced cleavage of Ang II to generate anti-inflammatory Ang-(1-7). 
This would upregulate the detrimental ACE-Ang II-AT1R axis and downregulate the 
protective ACE2-Ang-(1-7) axis (30,45). While plausible, this has yet to be 
unambiguously demonstrated and proven. However considering the 
pathophysiological role of the ACE2-Ang-(1-7)-MasR axis in diabetes mellitus, 
hypertension, atherosclerosis, heart disease and kidney disease, patients with 
underlying cardiovascular pathologies may have their diseases acutely exacerbated, 
or potentially chronically worsened by SARS-CoV-2 (46,47). Fundamental to many of 
these processes is inflammation and activation of immune responses, which in 
severe COVID-19 may be associated with cytokine storm (48).  
Inflammatory mechanisms of COVID-19 and cardiovascular consequences 
Acute and chronic inflammatory responses are at the core of COVID-19 pathology 
(49). This is clearly evidenced by the fact that dexamethasone is the only effective 
therapy in hospitalized patients as demonstrated by the RECOVERY trial (50,51). 
Severe immune dysregulation is characteristic of COVID-19 and ranges from 
peripheral blood lymphopenia to splenic atrophy as reported in post-mortem 
         
examinations (49). Circulating levels of pro-inflammatory cytokines are elevated in 
patients with COVID-19 and include classical cytokines such as IL-6 and TNF-a, as 
well as IL-7, IL-2, GM-CSF, C-X-C motif chemokine 10 (CXCL10), components of 
the cytokine release storm (51,52). Increased IL-6 is a clinical biomarker for 
cardiovascular morbidity and a predictor of mortality in COVID-19 (51,53). 
Inflammation mediates cardiovascular pathology, acting directly on cardiac and 
vascular cells, and through further propagation of cardiovascular inflammation.  
Mechanistically, COVID-19-related cytokines such as IL-6, IL-17 or TNF-a, induce 
oxidative stress and inflammation in endothelial and vascular smooth muscle cells, 
promoting micro-and macro-vascular disease (54,55). Oxidative stress is also key in 
IL-6-induced increases of adhesion molecule expression in endothelial cells. In 
addition to causing inflammation, a rapid surge in cytokine production is cardiotoxic 
inducing conduction abnormalities, atrial fibrillation, cardiac fibrosis and heart failure, 
phenomena observed in the acute phase of severe COVID-19 (56). Whether the 
cytokine storm and IL-6 increase in COVID-19 are transient or sustained processes 
remains unclear, but monitoring these biomarkers may be important as they may be 
predictive of complications in long-term COVID-19.  
While initial studies focused on cytokines involved in cytokine storm, subsequent 
analysis identified several distinct cellular immunophenotypes in patients with 
COVID-19. These studies identified inflammatory cells that may be responsible for 
rapid overproduction of cytokines in COVID-19. Using single cell RNA sequencing 
(scRNA-seq), a new immune phenotype in COVID-19 has been described, including 
a heterogeneous interferon-stimulated gene signature, downregulation of HLA class 
II and a developing neutrophil population (57). These features are related to severe 
         
outcomes, and therefore also with cardiovascular pathologies (58,59). While 
peripheral lymphopenia is a feature of severe COVID-19, high-dimensional 
cytometry revealed activation of T cell and B cell subsets in a proportion of patients 
with plasmablast responses reaching >30% of circulating B cells (59,60). 
Interestingly, another immunophenotype represented patients who presented with 
lymphocyte activation comparable to healthy controls. In COVID-19, CD8 T cell 
subset skewing and activation patterns  were observed, which can be  linked to T 
cell–derived cytokines (60) observed during cytokine storm. Such hyperactivated T 
lymphocytes are characterized by large fractions CCR6+ TH17 CD4+ cells as well as 
HLA-DR+ and CD38+ CD8+/CD4+ T cells,  as well as presence of cytotoxic granules 
in cytotoxic T (CD8) cells. Hyperactivated T cells and monocytes may account for, at 
least in part, the severe immune injury observed in cardiovascular disease (56, 
61,62).  
COVID-19 and cardiovascular inflammation  
Cardiac injury and acute myocarditis are recognised complications of acute viral 
conditions in general (63). Myocyte necrosis and mononuclear cell infiltrates are 
reported in cardiac biopsies from COVID-19 subjects. The most common 
pathological cause of myocyte necrosis appears to be microthrombi (64). This is 
consistent with numerous early reports of  fulminant myocarditis in COVID-19 (65). 
However the actual extent of myocarditis in COVID-19 is difficult to establish. 
SARS-CoV2 may directly infect human cardiac myocytes, as demonstrated using 
iPS derived cardiac myocytes and human myocardial slices, leading to viral 
replication inside cardiac myocytes (66). SARS-CoV-2-induced cytotoxic and 
proapoptotic effects leads to cardiomyocyte dysfunction. SARS-CoV-2 infection of 
cardiomyocytes in vitro was inhibited by the antiviral drug remdesivir (66). Viral 
         
infection and myocarditis in COVID-19 may also exacerbate features of cytokine 
storm and contribute to further heart muscle dysfunction (67). Cardiac injury in 
models of viral myocarditis leads to innate immunity activation with macrophage 
infiltration and overproduction of proinflammatory cytokines (68), influencing 
acquired immune responses involving CD4+ T helper cells and cytotoxic CD8+ T 
cells. ACE2 and other putative SARS Co-V2 receptors are found on numerous cell 
types in the heart, such as pericytes, and their expression is increased in 
cardiovascular disease including heart failure (69). Accordingly myocardial 
dysfunction may be caused by severe systemic inflammation and cytokine storm as 
well as by direct infection of cardiac myocytes. Together these drive a vicious circle 
of cardiac inflammation and dysfunction in COVID-19 mediating both short- and 
long-term cardiovascular consequences of this disease (figure 3).  
Inflammation and immune responses have also been demonstrated in the vascular 
system and there is emerging evidence that many of the cardiovascular 
complications and systemic pathologies associated with COVID-19 are due to 
endotheliitis and vasculitis (70-73). Moreover long term cardiovascular 
consequences of COVID-19 may be associated with sustained cytokine increase 
and persistent cardiovascular inflammation. In particular cellular immune changes 
related to distinct immune phenotypes of activated (CD14+CD16+) monocytes as 
well as lymphocytes have been implicated in long term cardiovascular sequelae of 
COVID-19 (74).  
Immunomodulation in COVID-19 
Considering the importance of the immune system and inflammation in COVID-19 
there has been enormous interest in targeting these processes therapeutically. Trials 
         
are currently under way to address the efficacy of immune targeted therapies in the 
prevention of severe COVID-19, which will have clear implications for its 
cardiovascular comorbidities.This includes therapeutic targeting of the IL-6 receptor 
(IL-6R) with tocilizumab which has been used in preventing and treating cytokine 
release storm in cancer, treatment of arthritis and giant cell or Takayasu arteritis and 
colchicine, a non-specific anti-inflammatory drug (75,76). Therefore it may provide an 
attractive possibility to target cytokine release storm in COVID-19, which would also 
have cardiovascular protective effects.  
Hypertension 
Initial studies at the onset of the pandemic reported high prevalence of hypertension 
and other comorbidities and mortality from COVID-19 (77,78). In a case-series study 
of 5,700 patients with COVID-19 in New York, hypertension (56.6%), obesity 
(41.7%), and diabetes (33.8%) were the most frequent comorbidities (77). In a large 
study of over 72,000 patients with COVID-19 (confirmed, suspected or clinically 
diagnosed), the overall case fatality rate was 2.3%, but this increased significantly in 
the presence of comorbidities (10.5% for cardiovascular disease, 7.3% for diabetes, 
and 6% for hypertension) (79). Findings from many studies in different countries 
show that patients with COVID-19 and hypertension have a higher mortality risk 
when compared with non-hypertensives (77-79).  
The relationship between hypertension and COVID-19 is complex with some studies 
failing to report an association. In patients with laboratory-confirmed COVID-19 
admitted to intensive care units at 65 USA hospitals there was no impact of 
hypertension on COVID-19 outcomes, although  BMI>40 and coronary artery 
disease were independent predictors of 28-day mortality (80). A multivariable 
         
analysis on adults with confirmed COVID‐19 hospitalized at two hospitals in Wuhan 
reported that hypertension marginally increased the risk of severe infection and 
increased risk of mortality only in combination with diabetes or other comorbidities 
(81). The OpenSAFELY analysis (82) incorporating primary care data from 
17,278,392 patients in England showed that when adjusted only for age and sex, 
hypertension was associated with a significantly  increased risk of death in patients 
with COVID-19. The authors also found strong evidence of interaction with age with 
hypertension associated with a higher risk up to the age of 70 years and a lower risk 
above 70 years (82). High blood pressure is a predictor of heart failure during 
hospitalization increased variability of systolic blood pressure and diastolic blood 
pressure is associated with increased risk of mortality and intensive care admission 
(83,84). Increase in fatal and adverse respiratory outcomes have also been 
demonstrated across the spectrum of blood pressure categories - normotensive 
through grade I, grade II and III hypertension (85).  
Indirect effect of COVID-19 on hypertension 
Diagnosis, monitoring and management of hypertension are likely to have been 
adversely affected by the COVID-19 pandemic with a reduction in primary care visits 
(86) in particular face-to-face appointments, less clinic blood pressure 
measurements and lack of public health screening events. Patients with 
hypertension may also have been less inclined to seek healthcare visits due to 
unwillingness to burden services, shielding due to high clinical risk or fear of 
contracting the SARS-CoV-2 virus leading to late presentation of cardiovascular 
disease and poorer outcomes (87).   
         
The COVID-19 pandemic has highlighted socioeconomic and health inequalities in 
many countries worldwide. There is an established link between socioeconomic 
factors (such as education, low-income and occupation) and the risk of hypertension 
and rate of blood pressure control (88). It is estimated that, compared to the least 
deprived areas, those from the most deprived areas are  more likely to have 
hypertension and cardiovascular complications whilst some ethnic groups are 
disproportionately affected with greater rates in blacks and Asians compared to 
whites (89). This increased risk may be, in part, explained by lifestyle factors 
including obesity, diet, physical inactivity, and alcohol intake (90). COVID-19 has 
adversely affected those of lower socioeconomic status with mortality rates twice as 
high than in the least deprived areas (91,92).   
Long term effect of COVID-19 on hypertension 
Long COVID is a distinct condition post-COVID-19 of unknown cause, but it is likely 
to be due at least partly to an inflammatory reaction and vasculitis (70,93). Even 
patients without symptoms of thromboembolic disease after COVID-19 may show 
signs of organ damage (94). The presence of considerable ongoing cardiovascular 
inflammation after recovery from COVID-19 illness is important because it may 
herald a considerable burden of hypertension and target organ damage down the 
line (95,96). The combination of potential residual heart and vascular inflammation 
along with perturbation of the RAS post-COVID-19 diagnosis may represent a nidus 
for new-onset hypertension and  heart failure and represent an insidious feature of 
long-COVID. The burden of hypertension (from new-onset and prevalent) as a 
consequence of the COVID-19 pandemic is unknown but given the scale of the 
infection especially among the young this will be a major concern for the future. 
 
         
RAS inhibitors, hypertension and COVID-19 
Considering the role of the RAS and specifically ACE2 in COVID-19 infection and 
pathophysiology, there has been enormous debate whether antihypertensive drugs 
that inhibit the RAS impact disease severity (97-101). Angiotensin-converting 
enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are considered 
first-line antihypertensive agents but also play a crucial role in the management of 
patients with renal disease, heart failure, myocardial infarction and other 
cardiovascular disorders. Both ACEI and ARBs reduce the AT1R-mediated effects of 
Ang II and decrease activity of the traditional ACE/Ang II/AT1R axis with possible 
unmasking of the ACE2/Ang (1-9) and Ang (1-7) pathway.  
These effects on the protective arm of the RAS, together with reduced AT1R  activity 
are thought to provide further tissue protection and to constitute an important part of 
the multifaceted mechanism of action of RAS blocking agents. It is therefore 
conceivable that patients at highest risk of more severe forms of COVID-19 benefit 
from the tissue protection offered by these drugs. Apart from immediate effects of 
ACEI and ARB on vascular tone and blood pressure there are numerous beneficial 
long-term effects related to their antifibrotic, antiproteinuric and anti-inflammatory 
actions. However, with ACE2 being the main receptor for the SARS-CoV-2 spike 
protein there has been some concern that upregulation of the ACE2 axis could 
increase the receptor availability for SARS-CoV-2 host cell entry and infection and 
more severe COVID-19. 
These concerns are based primarily on experimental data in rodent models. For 
example, studies in hypertensive rats treated with the ACEI lisinopril or the ARB 
losartan caused upregulation of cardiac ACE2 mRNA expression (102). It was 
         
concluded that increased Ang II metabolism by ACE2 contributes to the 
antihypertensive effects of these drugs (102). This upregulation of ACE2 mRNA 
caused concerns in the initial stages of the COVID-19 pandemic. Driven more by 
theoretical considerations than conclusive data a number of hypothesis and opinion 
papers were published causing confusion in the field as to whether ACEi and ARBs 
should be withdrawn in COVID-19 patients (103).  
On the other hand, some studies reported that inhibitors of the RAS have beneficial 
effects in patients with severe COVID-19  (104,105). There is now a large body of 
evidence that confirms that inhibitors of the RAS do not affect the risk of COVID-19. 
A large study in the Lombardy region of Italy showed that, because of the higher 
prevalence of cardiovascular risk factors, patients with COVID-19 were more likely to 
take RAS blocking agents but that the use of these drugs was not independently 
associated with the risk of COVID-19 (106). Another study in New York hospitals 
found no association between the likelihood of a positive COVID-19 test and use of 
any of the five major classes of antihypertensive agents (107). Other studies in the 
UK and China reported that patients on ACEI or ARB were at reduced risk of severe 
COVID-19 and that these drugs were not associated with increased risks of receiving 
intensive care unit care (108,109). Meta-analyses of studies into disease severity 
and mortality have further confirmed that ACEI and ARB are neither associated with 
all-cause mortality nor severe COVID-19 disease (109).  Overall there is now 
extensive and unequivocal evidence that ACEI and ARB can and should be 
continued in patients with COVID-19. Based on these data, learned societies, 
guideline committees and other scholars have published statements that withholding 
RAS blocking agents places patients at risk of immediate and long-term sequelae of 
         
hypertension and other cardiovascular diseases that outbalance the theoretical risk 
related to increased expression of a SARS-CoV-2 receptor (110-112).   
In clinical practice, however, there are situations where RAS blocking agents may 
need to be withheld, for example in patients with acute kidney injury or 
hyperkalaemia and particularly in patients with severe COVID-19 who are 
haemodynamically compromised. Likewise, it should be noted that there is no 
evidence that introduction of RAS blocking agents in patients with COVID-19 who 
have not been on such treatment prior to contracting the disease is associated with 
any better or worse outcome. Decisions to withhold ACEI or ARB should always be 
based on the clinical situation - independent of SARS-CoV-2 infection. Use of these 
drugs should always be guided by their evidence-based indications in cardiovascular 
and renal protection and not by possible effects on the course of COVID-19. Once 
COVID-19 has been successfully treated, patients should undergo thorough 
cardiovascular risk assessment, and RAS blocking agents as well as other primary 
and secondary preventative measures should be started or reintroduced based on a 
patient’s risk profile. The evolving evidence that SARS-CoV-2 infection increases 
cardiovascular risk in its own right should also be taken into account. 
Thromboembolic disease 
COVID-19, especially in hospitalized patients,  is associated with significant arterial 
and venous thrombotic complications, including myocardial infarction, ischemic 
stroke, pulmonary embolism and venous thromboembolism (113-115). Early and 
consistent clinical observations in China and New York reported that biochemical 
indices of coagulation were abnormal in COVID-19 with almost 100% of patients with 
severe disease having mild thrombocytopenia and elevated levels of D-dimer 
         
(116,117). Since then other prothrombotic abnormalities have been described in 
COVID-19 including increased levels of fibrinogen degradation products (FDP), 
factor VIII and antiphospholipid antibodies and decreased levels of protein C, protein 
S and antithrombin (118). Elevated levels of D-dimer and FDPs are closely 
associated with increased severity of disease and mortality, with D-dimer being an 
independent risk factor for death  (119,120). High levels of D-dimer are common in 
severe illness and are associated with seriousness and death in many severe viral 
infections including Ebola, influenza, HIV and Dengue (121,122). However recent 
studies indicate that arterial and venous thrombosis risk is higher in patients with 
COVID-19 than other forms of viral pneumonia, suggesting that pathophysiological 
processes are independent of immobilization associated with hospitalization (123).  
Initial studies described the coagulopathy of COVID-19 as DIC. However DIC 
severity correlates with platelet number and prolonged prothrombin time (PT), and 
not with fibrinogen and FDPs, which is what is observed in COVID-19. Accordingly 
the coagulopathy of COVID-19, typically defined by hypercoagulation associated 
with elevations in D-dimer and FDPs with mild thrombocytopenia and prolonged PT, 
may be distinct from DIC and likely reflects dysregulated hemostasis (124). 
Histopathology evidence that COVID-19 is associated with microvascular 
thromboembolic disease  
The first autopsy series from patients with COVID-19 in Wuhan described features of 
acute respiratory distress syndrome (ARDS) and evidence of small vessel occlusion, 
highlighting associated pulmonary microvascular thromboembolic disease (125). 
More recent post-mortem studies have provided further pathologic details including 
bilateral acute changes with diffuse alveolar damage with vascular congestion, intra-
         
alveolar edema, hemorrhage, proteinaceous exudate, macrophages, denudation and 
reactive hyperplasia of pneumocytes and patchy inflammatory cellular infiltration 
comprising multinucleated giant cells, lymphocytes (CD4+ve), eosinophils and 
neutrophils. A consistently reported feature in post-mortem analysis from many case 
series is microvascular thrombi, neutrophil extracellular traps (networks of 
extracellular neutrophil-derived DNA), and neutrophil-platelet aggregates contributing 
to extensive microvascular damage and thrombotic occlusion (126,127). These 
vascular changes have been attributable, in part, to dysregulation of the endothelial 
ACE2 receptor with associated bradykinin-mediated lung edema and pro-thrombotic 
state (127).  Beyond the lungs, autopsy findings reveal widespread microthrombi in 
many organs including the heart, kidneys and lungs and to a lesser extent in the 
brain (128). These phenomena may underlie multisystem organ failure in patients 
with severe forms of COVID-19, especially in African Americans (129).   
Mechanisms of COVID-19-associated coagulopathy 
The pathophysiology of thromboembolism in COVID-19 versus non–COVID-19 
disorders seems to be more platelet-sensitive with viral-mediated endothelial 
inflammation, and hypercoagulability associated with increased concentrations of 
coagulation factors, acquired antiphospholipid antibodies, and decreased 
concentrations of endogenous anticoagulant proteins. Factors that likely contribute to 
thromboembolic disease in COVID-19 include a combination of immobility, systemic 
inflammation, platelet activation, endothelial dysfunction and stasis of blood flow, 
which promote coagulation and consequent microvascular and macrovascular 
thrombosis (130).  Whether these processes are specific to SARS-CoV-2 infection or 
a thromboinflammatory consequence of severe viral disease is still unclear.  
         
In vitro studies demonstrated that SARS-CoV-2 infection promotes activation of 
platelets, neutrophils and endothelial cells, with associated activation of coagulation 
factors, thrombin generation, fibrin production, increased plasminogen activator 
inhibitor-1 (PAI-1):tissue plasminogen activator (t-PA) ratio and production of pro-
inflammatory cytokines, processes that promote hypercoagulation (131). In 
particular, direct viral infection of pneumocytes and endothelial cells promotes an 
immune and inflammatory response characterized by activation of T cells, 
neutrophils, macrophages, monocytes and platelets leading to cytokine production 
(IL-1, IL-6, IL-10, TNF), increased PAI-1 expression and consequent thrombus 
formation (114). Microthrombi in COVID-19 typically contain fibrin, platelets, 
neutrophils and neutrophil extracellular traps (NETs), which are tangles of  DNA from 
degenerated neutrophils (129). NETs further contribute to hypercoagulation by 
stimulating the extrinsic pathway and activating platelets (132).  
Thromboprophylaxis in COVID-19 
While there is a clear association between hypercoagulable states and COVID-19, it 
still remains unclear to what extent SARS-CoV-2 increases the risk of 
thromboembolic disease. Some studies failed to show differences in hospital-
associated venous thromboembolism in patients with COVID-19 versus patients with 
non-COVID-19 illness, suggesting that the coagulopathy is not specific to the virus, 
but rather due to the overall illness severity and complications of the disease (133). 
Nevertheless clinical guidelines suggest that thromboprophylaxis should be 
considered for all hospitalized patients with COVID-19 in the absence of 
contraindications (113,128,134).  
Early recognition and management of thromboembolism risk, based on CRP or D-
dimer levels and impending cytokine storm, based on serum ferritin, was associated 
         
with improved COVID-19 survival and hospital outcomes in a traffic light-driven 
personalized care approach (135).  Current guidelines from the American College of 
Chest Physicians (ACCP) suggest prophylaxis with low-molecular weight heparin or 
fondaparinux rather than direct oral anticoagulants or fractionated heparin in 
hospitalized patients with COVID-19 who do not have contraindications, such as 
bleeding (136). However optimal anticoagulation strategies are still unclear and 
prospective clinical trials to determine best therapeutic approaches are awaited.  
Heart disease 
Infection with viral pathogens has been suggested to associate with an increased 
risk of myocardial infarction (MI) and cardiovascular risk from the early 20th century, 
with a study reporting the highest incidence of heart disease within the first seven 
days of infection (136). Conversely, during the initial global spread of COVID-19 a 
reduction in the reported incidence of acute MI was observed compared with 
previous years (137,138). This was mainly due to behavioural changes by patients. 
They were more likely to die at home by delaying medical contacts, or eventually 
presenting ‘late’ (139). These behaviours can be explained by social anxiety towards 
hospitals, social distancing measures and reduction in usual outpatient activities may 
be implicated (138). Presenting late, with more complex illness inevitably will be 
more likely increase persisting chronic sequelae. 
Ischemia and non-ischemic myocardial injury 
Systemic pathogenic infection may pre-dispose to acute type 1 MI due to increased 
levels of circulating inflammatory cytokines in COVID-19 and resultant macrophage 
activity within atherosclerotic plaques, leading to coronary plaque rupture and 
thrombosis. Acute SARS-CoV-2 infection is also associated with a pro-thrombotic 
         
and pro-coagulable state; when combined with risk factors such as diabetes which is 
associated with impaired fibrinolysis and increased platelet activation, coronary 
thrombosis may occur (140).  
Type 2 MI secondary to supply and demand mismatch may occur during increased 
cardiac requirement in the presence of flow-limiting obstructive coronary disease, 
reduced blood oxygen concentration from COVID-19-related respiratory failure, 
arrhythmia, shock syndromes and acid-base or electrolyte disequilibrium. While 
cardiac enzymes are elevated in about 40% of patients hospitalized with COVID-19, 
type 2 MI should only be diagnosed in the presence of symptoms of myocardial 
ischemia, new ischemic ECG changes, the development of pathological q-waves or 
evidence of new regional wall motion abnormalities or loss of viable myocardium on 
imaging.  
Myocardial disease and myocarditis  
Cardiovascular injury is associated with history of prior cardiovascular disease, and 
elevated cardiac enzymes in the context of COVID-19 are associated with poorer 
outcomes compared with other causes of non-acute coronary syndromes or 
myocardial injury (140). Direct effect on the heart secondary to viral infiltration has 
been reported but appears to be uncommon (141). Cardiac pericytes and 
cardiomyocytes express ACE2 transmembrane receptor proteins, and fusion with the 
S protein of SARS-CoV-2 coronavirus is proposed as a source of cell invasion (142). 
However, to-date reports of direct cardiac infiltration in deceased patients at autopsy 
describe evidence of virus particles within the interstitium or macrophages rather 
than within cardiomyocytes  (143). 
         
Pathology studies have identified cardiac lymphocytic or eosinophilic infiltration 
either at autopsy or following endomyocardial biopsy in patients with COVID-19. The 
majority of reports are case studies or series with small sample size which limits 
assessment of incidence of myocarditis in hospitalized patients with COVID-19 
(144). Rather than direct effects of viral invasion, it has been reported that 
myocarditis in patients with COVID-19 is secondary to cytokine induced inflammatory 
myocarditis (144). 
Severe alteration to systemic microvascular and endothelial function have been 
reported in patients with COVID-19, particularly in those requiring mechanical 
ventilation (145). Coronary microvascular and endothelial dysfunction are therefore 
potential mechanisms of myocardial damage and persistent symptomatology 
following infection. In addition, there are reports of diffuse systemic vasculitis and 
endothelial involvement may also contribute to impaired microvascular function in 
patients with COVID-19 (70-72, 146). Microvascular thrombosis has previously been 
demonstrated at autopsy within pulmonary tissue and this may also be a cause of 
coronary microvascular necrosis or dysfunction (147). The results of mechanistic 
imaging studies which feature assessment of coronary microvascular perfusion and 
myographic vascular function following SARS-CoV-2 infection in patients with 
concomitant coronary assessment are awaited (148). 
Direct myocardial injury, inflammation and stress may contribute to Takotsubo 
cardiomyopathy,  a well documented acute cardiotoxic complication of  COVID-19 
infection (149,150). Mechanisms implicated in COVID-19-related cardiomyopathy 
include catecholamine surge and cytokine storm.  
         
Arrhythmia and sudden cardiac death 
Atrial fibrillation is the most frequently encountered arrhythmia newly diagnosed in 
patients with COVID-19 occurring in approximately 1 in 5 hospitalized patients and 
associated with increased likelihood of mortality (151). Premature ventricular 
complexes, ventricular tachycardia and bradycardia have also been reported 
although it is noted that pre-existing rhythm abnormalities were present in a 
proportion of these patients (152). Sudden cardiac death has been reported in case 
studies however, QTc prolonging medications were prescribed in these patients 
including quinolone antibiotics, or hydroxychloroquine which has been shown to 
have no benefit in hospitalized patients (153). 
Heart failure  
COVID-19 infection may predispose to developing acute heart failure either because 
of unmasking of subclinical preexisting heart failure or as a result of direct cardiac 
involvement. Mechanisms underling SARS-CoV-2-induced heart failure include 
virus-induced infiltration of inflammatory cells, pro-inflammatory cytokines, 
endothelial injury, micro-thrombosis, and hypoxia secondary to respiratory failure 
(154) Hospitalized COVID-19 patients show high likelihood of heart failure with 
preserved ejection fraction (HFpEF) that is associated with cardiac structural and 
functional abnormalities and myocardial injury and potential long-term heart disease 
(155). Accordingly detailed screening and  cardiac assessments including 
echocardiographic determination of left ventricular diastolic function and cardiac 
biomarkers have been suggested in the routine care of COVID-19 patients (156).   
Heart failure patients on advanced therapies including those needing heart 
transplantation require special care and involvement of advanced heart failure team 
         
members because they are at very high risk due to immunosuppression and 
hemodynamic instability (156). The International Society for Heart and Lung 
Transplantation guidelines suggest holding immunosuppressive drugs in moderate to 
severe presentations of COVID-19 (157). Successful heart transplantation has been 
described for COVID-19-associated post-infectious fulminant myocarditis (158)  
Diabetes and COVID-19 
In addition to hypertension and obesity, diabetes is strongly associated with COVID-
19 (159,160). Large population studies reported that people with type 2 diabetes are 
more than twice as likely to have died from COVID-19 than those without diabetes in 
the background population (after adjustment for age, sex, ethnicity, social deprivation 
and geographical region) (161).  The risk is even higher in people with type 1 
diabetes (159,160).  Patients with diabetes who developed fatal or intensive care 
unit-requiring COVID-19 have more comorbidities and complications (e.g. 
retinopathy) but also poorer glycaemic control and higher rates of previous 
ketoacidosis or hypoglycaemia hospitalisation (162).   
The mechanisms by which diabetes status, and in particular high blood glucose, 
predispose to poorer outcomes are currently under intense investigation.  It is highly 
relevant in this regard that the ACE2 receptor is expressed on pancreatic β-cells, 
potentially predisposing to cell damage and loss of endogenous insulin secretion 
(163).  Clinical experience indicates that people with diabetes who develop COVID-
19 are more likely to develop acute metabolic decompensation, including 
ketoacidosis, itself associated with poorer outcomes.  In keeping with the hypothesis 
of direct toxicity of SARS-CoV-2 to β-cells increased rates of diagnosis of type 1 
diabetes have been reported (163,164). 
         
However, additional mechanisms are clearly also in play. Hyperglycaemia is 
associated with elevated levels of proinflammatory cytokines, in particular IL-6: the 
resultant pro-inflammatory milieu is associated with susceptibility to infection with 
coronaviruses (163).  Moreover, associated oxidative stress facilitates entry of the 
virus into host cells and activation of hypoxia-inducible factor-1α, promoting rapid 
viral replication and the development of cytokine “storm” - a syndrome that often 
signals the sharp deterioration of people with COVID-19 after a few days of illness 
(163,164).  Such pathways are now being further investigated in more detail in large 
cohorts, particularly PHOSP-COVID which is currently recruiting 10,000 hospitalised 
survivors of COVID-19 in the UK (165). For example, it is not yet clear to what extent 
the benefits of therapeutic administration of dexamethasone in oxygen-requiring 
patients with diabetes and COVID-19 are offset by exacerbation of hyperglycaemia 
(166).  
The kidney, cardiovascular disease and COVID-19 
Although renal involvement was not a major feature of the early reports of COVID-19 
from Wuhan, it is now clear that together with the vascular system and heart, the 
kidneys are often affected in COVID-19 infection severe enough to require 
hospitalisation. The clinical manifestations of renal involvement in COVID-19 can 
vary in severity from haematuria and/or proteinuria, acute kidney injury (AKI) and the 
need for renal replacement therapy (RRT, i.e. dialysis or haemofiltration) (167-169). 
In patients with severe illness requiring management in intensive care units the 
proportion of patients requiring KRT is generally reported to be 20-30% (170,171). 
Acute kidney injury in patients with COVID-19 may lead to volume overload that 
could exacerbate pre-existing chronic heart failure, leading to poor outcomes.  
         
The major risk factors associated with developing biochemical AKI and need for RRT 
in COVID-19 are generally similar to those associated with more severe COVID-19 
infection, include male gender, diabetes, non white race, obesity, pre-existing 
chronic kidney disease, hypertension and age (170-172).  COVID-19 disease 
severity is also associated with increasing risk of requiring RRT. Whilst any critical 
illness e.g., pneumonia, major surgery, trauma, sepsis is associated with a risk of 
AKI and subsequent need for RRT, emerging data suggest that for an equivalent 
disease severity, COVID-19 infection appears more likely to provoke AKI (173). 
Similarly, in comparison to seasonal influenza, COVID-19 has a dramatically 
elevated risk of AKI and need for RRT (17469). 
Numerous pathophysiological mechanisms have been proposed to explain the 
preponderance of severe COVID-19 infection to cause AKI. First, like any critical 
illness, shock and renal hypoperfusion will lead to renal ischaemia and acute tubular 
necrosis (ATN). The role of systemic inflammation and cardiovascular disease  in the 
setting of COVID-19 may well potentiate AKI, although the specific contribution is 
unknown. Similar to cardiac cells, the virus has been demonstrated to directly infect 
and replicate in kidney cell (175). In the setting of severe COVID-19 immune 
dysregulation, complement dysregulation have all been postulated as being 
implicated in the development of kidney disease (176). Furthermore, 
hypercoagulability and thromboembolic disease associated with COVID-19 may 
further compromise renal perfusion and this may lead to transient renal ischemia or 
at its most extreme renal infarction has been described (177).  
The predominant message from epidemiological studies of COVID-19 is that severe 
COVID-19 is associated with a prevalence and severity of AKI out of keeping with 
         
the severity of renal insult observed with similar critical illnesses. Whether there is a 
specific effect of SARS-CoV-2 on the kidney is slightly less clear. Much of the 
original rationale for the disproportionate effect of SARS-CoV-2 on the kidney rested 
on the high expression of ACE2 in the proximal tubule of the kidney, suggesting the 
viral invasion may be specific to the kidney in a similar manner to the invasion of 
lung tissue (178). Some post-mortem studies report that SARS-CoV-2 exhibits renal 
tropism with evidence of direct infection with viral glomerular predilection (179). 
However, other renal histology of post-mortem studies of patients with severe 
COVID-19 have mainly demonstrated severe ATN which may be a non-specific 
finding simply representing severe critical illness with limited or no evidence of viral 
infection in the kidney (180).   
Percutaneous renal biopsy is infrequently performed in patients with severe COVID-
19 and may therefore be reserved for patients with atypical features such as 
disproportionate severity of AKI compared to the clinical course of the illness or 
heavy proteinuria. In those series of patients with COVID-19 who have clinically 
indicated kidney biopsies, a range of renal pathological lesions have been observed, 
supporting the notion that COVID-19 non-specifically triggers renal lesions including 
acute tubular necrosis, thrombotic microangiopathy, collapsing glomerulopathy, and 
various glomerulonephritides (181,182). Notably SARS-CoV-2 was not demonstrated 
in renal tissue in these native and kidney biopsy transplant series making it hard to 
draw conclusions on the specific nature of the renal insult directly attributable to 
COVID-19. 
The presence of AKI is associated with increased risk of mortality in patients with 
COVID-19, although whether this simply represents a marker of severe infection or a 
         
specific implication of AKI is challenging to dissociate (182,183). Knowledge of the 
longer-term implications of cardiovascular and renal involvement in COVID-19 are 
still evolving. It seems likely that many patients with kidney disease will not return to 
their pre-COVID-19 renal function.  Longer term follow up studies will inform this. 
Existing data suggest that 25-35% patients have not returned to baseline kidney 
function at the time of hospital discharge and hence have de novo or more severe 
CKD than before COVID-19 infection (168,169,183).  
Postural Orthostatic Tachycardia Syndrome and COVID-19 
Early in the pandemic it became apparent that symptoms of COVID-19 could persist 
after the acute illness and that many patients who recover from COVID-19 infection 
experience symptoms for many months after recovery. This condition, called ‘long 
COVID-19’, ‘long haulers’ or ‘post-acute sequelae of SARS-CoV-2 infection’ is 
associated with multiple cardiopulmonary and neurological symptoms including 
severe chronic fatigue, palpitations, chest pain, breathlessness and dysautonomia, 
features that are characteristic of postural tachycardia syndrome (POTS) (184-186). 
POTS impacts heart rate, blood pressure and cardiac function and  is caused by 
many factors including viral infections (187). While it still remains unclear whether 
SARS-CoV2 triggers POTS, emerging evidence indicates a close association 
between COVID-19 and POTS-like symptoms. Current treatment strategies focuses 
primarily on lifestyle modifications, and salt and fluid repletion (185-187). The 
potential health burden of long COVID-POTS is significant, which has  prompted a 
Statement paper on the topic by the American Autonomic Society (188). 
 
 
         
Management of cardiovascular disease in patients at risk of COVID-19 
It is beyond the scope of the present review to discuss specific protocols in the 
treatment of patients with cardiovascular disease who are at risk of COVID-19, but 
the reader is referred to current guidance and opinion papers (189-193). In general 
management decisions in the treatment of COVID-19 patients with pre-existing 
cardiovascular disease should be considered on a case-to-case basis. 
Cardiovascular patients should be protected as much as possible from exposure to 
SARS-CoV2-infected individuals. Unless otherwise contra-indicated, cardiovascular 
patients should be encouraged to be vaccinated against SARS-CoV2.  
Conclusion 
While there is a clear association between cardiovascular disease and COVID-19 it 
should be highlighted that many of the studies are retrospective and hence subject to 
bias and confounding. Dissociating the very strong effect of age on COVID-19 
outcomes with other comorbidities whose prevalence increase with age, namely 
hypertension, diabetes and other cardiovascular diseases is challenging. However, 
resolving this relationship is critical as this will have implications on management of 
patients. In the same light, while heart injury seems to be common in patients with 
severe COVID-19, the long-term health implications and potential ‘lingering’ effects 
of cardiovascular damage remain unclear. Moreover, the relevance of cardiovascular 
disease in SARS-CoV-2 positive, asymptomatic COVID-19 patients is unknown and 
as stated by Anthony Fauci MD, director of the National Institute of Allergy and 
Infectious Diseases and reported by Abbasi, the cardiac effects ‘may be clinically 
inconsequential, or could lead to chronic effects’ (194). In addition the long-term 
         
impact of the indirect effects of COVID-19, such as delayed treatment of 
cardiovascular disease, is still unclear. 
There is still no curative therapy for COVID-19, but the successful repurposing of 
drugs such as remdesivir and dexamethasone, together with successful 
immunisation programmes will likely improve the situation. However, as variants of 
SARS-CoV-2 emerge for which current vaccines offer reduced protection, it is 
increasingly likely that the pandemic will continue in some form for several years, 
with cardiovascular complications of COVID-19 remaining a clinical challenge.  This 
has led to urgent calls for increased research into relevant mechanisms and 
improved prevention and care of patients with cardiovascular and cardiometabolic 
disease.  
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Figure 1. Diagram demonstrating components of the renin angiotensin system 
and the multifunctional role of ACE2. ACE2 acts primarily as an enzyme to 
generate Ang-(1-9) and Ang-(1-7) from Ang I and Ang II respectively. ACE2 is also 
the receptor for SARS-CoV-2 that causes COVID-2. 
 
 
         
 
 
Figure 2. COVID-19 and cardiovascular and cardiometabolic disease. COVID-
19, is a respiratory disease but is also associated with vascular dysfunction, 
coagulopathies, myocardial injury, metabolic disturbances, kidney injury and 
systemic inflammation. These processes contribute to widespread cardiovascular 
and metabolic pathologies including hypertension, heart disease, thromboembolic 





         
 
 
Figure 3. Central role of inflammation and cytokine storm in mediating 
cardiovascular consequences of COVID-19. SARS-CoV-2 infection affects the 
cardiovascular system in two-ways. Firstly, through direct viral invasion using entry 
receptor ACE2 (angiotensin converting enzyme); secondly it evokes severe immune 
response resulting in cytokine storm characterized by systemic overproduction of  
cytokines such as IL-6, IL-7, IL-22, IL-17 or CXCL10. These cytokines further 
perpetuate inflammation and cause activation and dysfunction of various cell types in 
the heart, vasculature and brain leading to cardiovascular manifestations. 
Immunophenotyping studies show that cellular responses in COVID-19 differ 
between patients and may take a form of several immunophenotypes. Mf- 
macrophage; EMRA – effector memory expressing CD45RA; Tfh- T follicular helper 
cells; ACE2- angiotensin converting enzyme 2; t-bet – t-box transcription factor. 
         
